Voloridge Investment Management
APGE

Voloridge Investment Management’s Apogee Therapeutics APGE Stock Holding History

Voloridge Investment Management’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-167,991
Closed -$6.28M – 1155
2025
Q1 		$6.28M Buy
167,991
+126,885
+309% +$4.91M 0.02% 717
2024
Q4 		$1.86M Sell
41,106
-641
-2% -$32.7K 0.01% 953
2024
Q3 		$2.45M Sell
41,747
-133,067
-76% -$6.38M 0.01% 910
2024
Q2 		$6.88M Buy
+174,814
New +$8.49M 0.03% 667

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Voloridge Investment Management's APGE Position: Q2 2025 in Review

Voloridge Investment Management sold out of Apogee Therapeutics (APGE) in Q2 2025, closing a stake of 167,991 shares — an estimated $6.28M sold.

Voloridge Investment Management first reported a position in APGE in Q2 2024 and held it in 4 quarters. The position peaked at $6.88M in Q2 2024. 182 funds tracked by Wall St. Rank hold APGE as of Q2 2025.

  • Voloridge Investment Management reported no remaining Apogee Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Voloridge Investment Management sold 167,991 Apogee Therapeutics shares in Q2 2025, an estimated $6.28M.
  • Voloridge Investment Management first reported a position in Apogee Therapeutics in Q2 2024 and held it in 4 quarters.
  • Voloridge Investment Management's Apogee Therapeutics position peaked at $6.88M in Q2 2024.
  • 182 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2025.

Based on Voloridge Investment Management's 13F filing for Q2 2025, filed 14 Aug 2025.